Abstract 703P
Background
HER2 overexpression and/or amplification has been reported as predictive factor to HER2 targeted therapy in breast and gastric cancer, whereas HER3 is emerging as a potential resistance factor. The aim of this study was to perform a systematic review and meta-analysis of the HER2 and HER3 up-regulation in biliary tract cancers (BTCs).
Methods
An electronic search of MEDLINE, ASCO, ESMO and AACR was performed to identify studies reporting HER2 and/or HER3 membrane protein expression by immunohistochemistry (IHC) and/or gene amplification by in situ hybridisation (ISH) in BTCs.
Results
Out of 440 studies screened, 40 met the inclusion criteria. Globally, HER2 expression rate was 26.5% (95% CI, 18.9% - 34.1%). Studies were classified as “high-quality” (HQ; 27 studies) [IHC overexpression defined as presence of moderate/strong staining] and “low-quality” (11 studies) [“any” expression was considered positive]. When HQ studies were analysed, extra-hepatic BTCs (EH-BTCs) showed a higher HER2 overexpression rate compared to intrahepatic cholangiocarcinoma (IHCC) [19.9% (95% CI, 12.8 – 27.1%) vs. 4.8% (95% CI, 0 – 14.5%); p-value 0.0049]. HER2 amplification rate was higher in those patients selected by HER2 overexpression [57.6% (95% CI, 16.2 - 99%)] compared to “unselected” patients [17.9% (95% CI, 0.1 – 35.4%); p-value 0.0072]. HER3 overexpression (4/4 HQ studies) and amplification rates were 27.9% (95% CI, 9.7 - 46.1%) and 26.5% (one study), respectively.
Conclusions
Up to 20% of EH-BTCs might be HER2 overexpressed, ∼60% of HER2 overexpressed BTCs can be considered amplified while HER3 is overexpressed or amplified in ∼25% of BTCs. These findings may be considered in future trial development.
| HER2 status | No. studies | Up-regulation rate mean (95% CI, %) | P-Value | |
|---|---|---|---|---|
| Overall expression by IHC | 38 | 26.5% (18.9 - 34.1%) | ||
| Region of provenience | Asia | 17 | 28.4% (14.5 - 42.3%) | |
| West | 16 | 19.7% (10.1 - 29.2%) | 0.4936 | |
| IHC assessment | Low quality | 11 | 41.7% (22.9 - 60.5%) | |
| High quality | 27 | 20.3% (13.2 - 27.5%) | 0.0336 | |
| Site of Primary regardless IHC scoring | IHCC | 12 | 21.1% (2.3 - 39.7%) | |
| EHBTC | 32 | 22.5% (15.5 - 29.5%) | 0.2557 | |
| EHCC | 11 | 17.4% ( 3.4 - 31.4%) | 0.4752 | |
| GBC | 14 | 24.2% (14.1 - 34.3%) | 0.2339 | |
| AC | 7 | 27.2% (7.2 - 47.2%) | 0.4652 | |
| Site of Primary by HQ/IHC | IHCC | 8 | 4.8% (0 - 14.5%) | |
| EHBTC | 28 | 19.9% (12.8 - 27.1%) | 0.0049 | |
| EHCC | 11 | 17.4% ( 3.4 - 31.4%) | 0.0134 | |
| GBC | 12 | 19.1% ( 11.2 - 26.8%) | 0.0123 | |
| AC | 5 | 27.9% (0 - 60.7%) | 0.0642 | |
| Overall amplification by ISH | 16 | 30.1% (11.7 - 48.5%) | ||
| Site of Primary | IHCC | 6 | 17.6% (0 - 60.1%) | |
| EHBTC | 14 | 22.5% (7.9 - 37.2%) | 0.0468 | |
| Amplification by selection population | No | 12 | 17.9% (0.1 - 35.4%) | |
| Yes | 5 | 57.6% (16.2 - 99%) | 0.0072 |
Clinical trial identification
Legal entity responsible for the study
Istituto Europeo di Oncologia, Milano (IT)
Funding
“Clinical Unit Visit” ESMO fellowship
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract